{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-002595","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.845870+00:00","generated_at":"2026-05-25T01:20:50.930080+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Coherus swings to FY 2024 net income of $28.5M; UDENYCA divestiture on track","bullets":["FY 2024 net income $28.5M ($0.25 diluted EPS) vs net loss $237.9M in FY 2023; revenue $267M, +4%.","UDENYCA net revenue $206M (+62% YoY); LOQTORZI Q4 revenue $7.5M, +29% QoQ.","Non-GAAP net loss $86.3M ($0.75 loss per share) improved from $186.2M in FY 2023.","UDENYCA divestiture up to $558.4M; shareholder vote March 11, expected close late Q1/early Q2 2025.","Post-divestiture projected cash ~$250M, cash runway >2 years; headcount reduction ~30%."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-002595","json":"https://secwatch.observer/filing/0001558370-25-002595.json","markdown":"https://secwatch.observer/filing/0001558370-25-002595.md","text":"https://secwatch.observer/filing/0001558370-25-002595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025002595/0001558370-25-002595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025002595/chrs-20250310x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:20:50.930080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}